A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas

NCT07750353 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Unresectable Thymic Carcinoma

Interventions

DRUG: Sacituzumab Tirumotecan (Sac-TMT)

Sponsor

National Cancer Center, Japan